AstraZeneca Annual Report and Form 20-F Information 2016金沙正规娱乐官网


金沙登录网址


金沙登录网址

2017 should be a turning point in our journey as we bring new medicines to patients across the globe.

Pascal Soriot, Chief Executive Officer

金沙登录网址

Total Revenue*
金沙登录网址

金沙正规娱乐官网


* As detailed on page 142 of the downloadable PDF of the Annual Report, Total Revenue consists of Product Sales and Externalisation Revenue.

Net cash flow from operating activities
金沙登录网址

金沙正规娱乐官网




金沙登录网址

金沙登录网址

A global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.


金沙登录网址

Our strategic priorities reflect how we are working to achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines.





金沙登录网址

金沙登录网址

Distinctive R&D capabilities: small molecule and biologic medicine, including immunotherapies and protein engineering, as well as devices, biomarkers and translational science.



金沙登录网址



金沙登录网址




金沙登录网址


Commercial Highlights:
金沙登录网址

  • Emerging Markets: Stable (growth of 6% at CER), supported by China, up 4% (10% at CER) to $2,636 million
  • Diabetes: Growth of 9% (11% at CER), as Farxiga/Forxiga became our largest-selling Diabetes medicine
  • Japan: Sales up 8% (decline of 3% at CER), reflecting exchange rate impact and a biennial price reduction
  • Brilinta/Brilique sales grew by 36% (39% at CER)
  • Respiratory: A decline of 5% (3% at CER), reflecting US pricing pressure for Symbicort
  • New Oncology: Strong sales with Tagrisso delivering sales of $423 million in its first full year

金沙登录网址



金沙登录网址

1) California, US  2) Gaithersburg, MD, US 3) Boston, MA, US  4) Gothenburg, Sweden
5) Shanghai, China  6) Osaka, Japan


金沙正规娱乐官网

金沙正规娱乐官网

金沙正规娱乐官网

金沙正规娱乐官网


Cambridge, UK (HQ)


Gothenburg, Sweden


Gaithersburg, Maryland US



金沙登录网址

金沙登录网址

Our capital-allocation priorities strike a balance between the interests of the business, our financial creditors and shareholders, and support our progressive dividend policy.



Distributions to shareholders $m 2016 2015 2014
Dividends
3,561
3,486
3,521
Proceeds from issue of shares
(47) (43) (279)
Total 3,514 3,443 3,242

Dividend per Ordinary Share $          2016 2015 2014
Dividend per Ordinary Share
2.80 2.80 2.80

Dividend per Ordinary Share for 2016    $
Pence
SEK
Payment Date
First interim dividend 0.90
68.7
7.81
12 September 2016
Second interim dividend 1.90
150.2
16.57
20 March 2017
Total 2.80
218.9
24.38
 

AstraZeneca’s Directors take very seriously their responsibility to have a robust governance structure in place.

Leif Johansson, Chairman